This latest expansion of the company's Peakexplorer libraries is specifically designed, synthesised and characterised for screening against aminergic G-protein coupled receptor (GPCR) targets
Peakdale Molecular is launching the latest in its line of G-protein coupled receptor (GPCR) libraries, Peakexplorer G5.
This latest expansion of the company's Peakexplorer libraries is specifically designed, synthesised and characterised for screening against aminergic GPCR targets.
Peakexplorer G5 is based on eight novel chemotypes, covering over 1200 compounds, and brings the total offering of the Peakexplorer libraries to over 27 major chemotypes and more than 6000 purified and characterised drug-like compounds.
The libraries, created using Peakdales innovative chemistry expertise, include chemotypes derived from novel Peakdale compounds and were designed using De Novo Pharmaceuticals's in silico pharmacophore modelling and virtual screening algorithms.
Ray Fisher, Peakdale Molecular's commercial director, commented, "50% of all marketed drugs act on GPCRs, covering almost every therapeutic application.
"Combining our medicinal chemists' expertise and our computational capabilities has provided compounds with excellent drug-like properties and demonstrates our commitment to providing our customers with a head start in their discovery activities.
"Building on the success of these we are pleased to announce that we now plan to develop libraries focusing on other classes of GPCRs".
Peakdale is also extending its Peakexplorer range to include kinase libraries, starting with c-Abl tyrosine kinase.
This will further increase Peakdale's offering of drug-like screening compounds to produce high quality, patentable leads in the drive for new drugs.
Peakdale Molecular was founded in 1992.
Today, the company's customers include global pharmaceutical majors and an increasing number of biotechnology companies.
Its team of chemists combines experience in pharmaceutical R and D and process development, fine chemicals, parallel synthesis and medicinal chemistry to deliver unique chemistry solutions to a range of drug discovery challenges.
Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research chemistry.
